Aimee Lenar compensation by year
Bausch Health Companies Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $300,000 | $650,000 |
| Bonus | $400,000 | $0 |
| Stock awards | $1,056,657 | $1,958,861 |
| Option awards | $0 | $0 |
| Non-equity incentive | $227,530 | $628,880 |
| Pension and deferred compensation | $0 | $0 |
| All other | $2,250 | $26,750 |
| Total | $1,986,437 | $3,264,491 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bausch Health Companies Inc. DEF 14A filed April 8, 2026, accession 0001140361-26-013816, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Bausch Health Companies Inc. filed document, accession 0001140361-26-013816. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 216,622 | $1,505,522 | — |
| RSU | 108,311 | $752,761 | — |
| RSU | 96,235 | $668,833 | — |
| RSU | 30,847 | $214,387 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Bausch Health Companies Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 8, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-19 | Sale | 10b5-1 | 36,827 | $7.03 | 334,853 |
| 2026-07-17 | Tax withholding | — | 5,260 | $4.83 | 371,680 |
| 2026-07-15 | Tax withholding | — | 23,395 | $4.89 | 376,940 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Bausch Health Companies’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Thomas Appio | Chief Executive Officer | $16,877,326 |
| Jean-Jacques Charhon | Executive Vice President, Chief Financial Officer | $4,905,075 |
| Seana Carson | Executive Vice President, General Counsel | $4,261,607 |
| Aimee Lenar · this page | Executive Vice President, US Pharma | $3,264,491 |
Aimee Lenar's compensation dossier, Bausch Health Companies
You have read Aimee Lenar's totals and holdings. The dossier adds each equity grant Bausch Health Companies disclosed for Aimee Lenar and Bausch Health Companies's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Bausch Health Companies compensation record
free company briefThis page is one person within Bausch Health Companies's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Bausch Health Companies proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Bausch Health Companies's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Bausch Health Companies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BHC
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.